Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Ocular Therapeut (OCUL)

Ocular Therapeut (OCUL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,336,345
  • Shares Outstanding, K 157,217
  • Annual Sales, $ 58,440 K
  • Annual Income, $ -80,740 K
  • EBIT $ -141 M
  • EBITDA $ -138 M
  • 60-Month Beta 1.20
  • Price/Sales 22.87
  • Price/Cash Flow N/A
  • Price/Book 3.76

Options Overview Details

View History
  • Implied Volatility 69.02% ( -48.82%)
  • Historical Volatility 57.39%
  • IV Percentile 9%
  • IV Rank 15.92%
  • IV High 252.21% on 06/12/24
  • IV Low 34.35% on 06/11/24
  • Put/Call Vol Ratio 0.02
  • Today's Volume 58
  • Volume Avg (30-Day) 291
  • Put/Call OI Ratio 0.27
  • Today's Open Interest 16,240
  • Open Int (30-Day) 20,695

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.23
  • Number of Estimates 6
  • High Estimate -0.14
  • Low Estimate -0.28
  • Prior Year -0.28
  • Growth Rate Est. (year over year) +17.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.15 +5.03%
on 12/18/24
10.25 -16.49%
on 11/27/24
-0.27 (-3.06%)
since 11/22/24
3-Month
8.15 +5.03%
on 12/18/24
11.77 -27.30%
on 10/28/24
+0.10 (+1.18%)
since 09/23/24
52-Week
3.76 +127.67%
on 01/19/24
11.77 -27.30%
on 10/28/24
+4.42 (+106.76%)
since 12/22/23

Most Recent Stories

More News
Ocular Therapeutixâ„¢ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

OCUL : 8.56 (+0.71%)
Ocular Therapeutix, Inc. to Present at 43rd Annual J.P. Morgan Healthcare Conference in January 2025

Ocular Therapeutix, Inc. will present at the J.P. Morgan Healthcare Conference on January 13, 2025, in San Francisco.Quiver AI SummaryOcular Therapeutix, Inc. announced that it will present at the 43rd...

OCUL : 8.56 (+0.71%)
Ocular Therapeutixâ„¢ to Present at the 43rd Annual J.P. Morgan Healthcare Conference

OCUL : 8.56 (+0.71%)
Ocular Therapeutix Initiates First Registrational Trial SOL-1 for AXPAXLIâ„¢ in Wet AMD with Topline Data Expected Q4 2025

Ocular Therapeutix announced significant progress in the SOL-1 trial for AXPAXLIâ„¢, aimed at treating wet AMD.Quiver AI SummaryOcular Therapeutix, Inc. has announced that it has successfully randomized...

OCUL : 8.56 (+0.71%)
Ocular Therapeutixâ„¢ Announces More Than 300 Subjects Randomized in SOL-1

OCUL : 8.56 (+0.71%)
Insider Sale: Chief Scientific Officer of $OCUL (OCUL) Sells 2,948 Shares

Jeffrey S. Heier, the Chief Scientific Officer of $OCUL ($OCUL), sold 2,948 shares of the company on 11-25-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately...

OCUL : 8.56 (+0.71%)
Ocular Therapeutix, Inc. to Participate in December Investor and Scientific Conferences

Ocular Therapeutix will participate in December conferences highlighting advancements in retinal disease therapies and ongoing clinical trials.Quiver AI SummaryOcular Therapeutix, Inc., a biopharmaceutical...

OCUL : 8.56 (+0.71%)
Ocular Therapeutixâ„¢ to Participate in December Investor and Scientific Conferences

OCUL : 8.56 (+0.71%)
Ocular Therapeutix: Q3 Earnings Snapshot

Ocular Therapeutix: Q3 Earnings Snapshot

OCUL : 8.56 (+0.71%)
Ocular Therapeutixâ„¢ Reports Third Quarter 2024 Results and Business Highlights

OCUL : 8.56 (+0.71%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Ocular Therapeutix, Inc. is a biopharmaceutical company. It is focused on the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. The Company develops and markets eye care products. Ocular...

See More

Key Turning Points

3rd Resistance Point 9.01
2nd Resistance Point 8.84
1st Resistance Point 8.70
Last Price 8.56
1st Support Level 8.39
2nd Support Level 8.21
3rd Support Level 8.07

See More

52-Week High 11.77
Fibonacci 61.8% 8.71
Last Price 8.56
Fibonacci 50% 7.77
Fibonacci 38.2% 6.82
52-Week Low 3.76

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar